Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA5 | P31644 | 8/20 | 0.48 |
| ▸ | HPGD | P15428 | 5/20 | 0.46 |
| ▸ | GRM5 | P41594 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12844179 | 0.81 | HRH3 (0.54) | HPGDGRM5HRH3RAB9AALDH1A1 | |
| SCHEMBL12844390 | 0.81 | HRH3 (0.57) | HPGDGRM5HRH3RAB9AALDH1A1 | |
| SCHEMBL18199107 | 0.79 | GRM5 (0.54) | HPGDGRM5HRH3RAB9A | |
| SCHEMBL12776443 | 0.78 | HPGD (0.49) | GABRA5HPGDGRM5RAB9AALDH1A1 | |
| SCHEMBL23733489 | 0.78 | HRH3 (0.54) | HPGDHRH3RAB9AALDH1A1HSD17B10 | |
| SCHEMBL26421763 | 0.78 | SIGMAR1 (0.50) | HPGDHRH3RAB9ASMN1; SMN2 | |
| SCHEMBL21267333 | 0.78 | SMN1; SMN2 (0.65) | HPGDGRM5HRH3RAB9AALDH1A1 | |
| SCHEMBL22876967 | 0.76 | L3MBTL3 (0.65) | HRH3RAB9A | |
| SCHEMBL16712647 | 0.76 | HRH3 (0.72) | HRH3 | |
| SCHEMBL21414447 | 0.75 | ALDH1A1 (0.55) | HRH3RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7902373-B2 | asthma; for treating prostaglandin D2 mediated diseases; e.g. 6-(3-fluorophenyl)-N-[1-(1-methyl-1H-tetrazol-5-yl)piperidin-4-yl]nicotinamide | PFIZER INC (US) | 2011-03-08 | — | — | US | disclosed |
| US-20080146569-A1 | Nicotinamide Derivatives | PFIZER INC. | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146569-A1 | Nicotinamide Derivatives | NNT, NAMPT, NADK | GABRA5 1998/4885HPGD 18/4885GRM5 3073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.